Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2010

01-09-2010 | Invited Review

Opportunities for clinical research in meningioma

Authors: Michael A. Vogelbaum, C. Leland Rogers, Mark A. Linskey, Minesh P. Mehta

Published in: Journal of Neuro-Oncology | Issue 3/2010

Login to get access

Abstract

Meningiomas, when benign, are commonly treated with surgical resection alone. However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival. In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials. In this review, we discuss a number of trials that were attempted and/or completed by cooperative groups or clinical consortia, and describe areas of clearly unmet need in terms of defining the optimal treatment regimens. Finally, we discuss ongoing efforts to develop new trials to more definitively address important therapeutic questions.
Literature
1.
go back to reference Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39CrossRefPubMed Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39CrossRefPubMed
2.
go back to reference Kinjo T, al-Mefty O, Kanaan I (1993) Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33(3):394–399CrossRefPubMed Kinjo T, al-Mefty O, Kanaan I (1993) Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33(3):394–399CrossRefPubMed
3.
go back to reference Stafford S, Perry A, Suman V, Meyer F, Scheithauer B, Lohse C et al (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73(10):936–942CrossRefPubMed Stafford S, Perry A, Suman V, Meyer F, Scheithauer B, Lohse C et al (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73(10):936–942CrossRefPubMed
4.
go back to reference Perry A, Scheithauer B, Stafford S, Lohse C, Wollan P (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85(9):2046–2056PubMed Perry A, Scheithauer B, Stafford S, Lohse C, Wollan P (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85(9):2046–2056PubMed
5.
go back to reference Kuratsu J, Kochi M, Ushio Y (2000) Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92(5):766–770CrossRefPubMed Kuratsu J, Kochi M, Ushio Y (2000) Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 92(5):766–770CrossRefPubMed
6.
go back to reference Claus E, Bondy M, Schildkraut J, Wiemels J, Wrensch M, Black P (2005) Epidemiology of intracranial meningioma. Neurosurgery 57(6):1088–1095CrossRefPubMed Claus E, Bondy M, Schildkraut J, Wiemels J, Wrensch M, Black P (2005) Epidemiology of intracranial meningioma. Neurosurgery 57(6):1088–1095CrossRefPubMed
7.
go back to reference Jääskeläinen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26(5):461–469CrossRefPubMed Jääskeläinen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26(5):461–469CrossRefPubMed
8.
go back to reference Jung H, Yoo H, Paek S, Choi K (2000) Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery 46(3):567–574CrossRefPubMed Jung H, Yoo H, Paek S, Choi K (2000) Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery 46(3):567–574CrossRefPubMed
9.
go back to reference Taylor BJ, Marcus RJ, Friedman W, Ballinger WJ, Million R (1988) The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15(2):299–304PubMed Taylor BJ, Marcus RJ, Friedman W, Ballinger WJ, Million R (1988) The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15(2):299–304PubMed
10.
go back to reference Miralbell R, Linggood R, de la Monte S, Convery K, Munzenrider J, Mirimanoff R (1992) The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13(2):157–164CrossRefPubMed Miralbell R, Linggood R, de la Monte S, Convery K, Munzenrider J, Mirimanoff R (1992) The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13(2):157–164CrossRefPubMed
11.
go back to reference Condra K, Buatti J, Mendenhall W, Friedman W, Marcus RJ, Rhoton A (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39(2):427–436PubMed Condra K, Buatti J, Mendenhall W, Friedman W, Marcus RJ, Rhoton A (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39(2):427–436PubMed
12.
go back to reference Smith S, Boddu S, Macarthur D (2007) Atypical meningiomas: WHO moved the goalposts? Br J Neurosurg 21(6):588–592CrossRefPubMed Smith S, Boddu S, Macarthur D (2007) Atypical meningiomas: WHO moved the goalposts? Br J Neurosurg 21(6):588–592CrossRefPubMed
13.
go back to reference Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31(2):141–149CrossRefPubMed Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31(2):141–149CrossRefPubMed
14.
go back to reference Riemenschneider M, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 12:1045–1054CrossRef Riemenschneider M, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 12:1045–1054CrossRef
15.
go back to reference Pearson B, Markert J, Fisher W, Guthrie B, Fiveash J, Palmer C et al (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24(5):E3CrossRefPubMed Pearson B, Markert J, Fisher W, Guthrie B, Fiveash J, Palmer C et al (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24(5):E3CrossRefPubMed
16.
go back to reference Aghi M, Carter B, Cosgrove G, Ojemann R, Amin-Hanjani S, Martuza R et al (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64(1):56–60CrossRefPubMed Aghi M, Carter B, Cosgrove G, Ojemann R, Amin-Hanjani S, Martuza R et al (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64(1):56–60CrossRefPubMed
17.
go back to reference Ayerbe J, Lobato R, de la Cruz J, Alday R, Rivas J, Gómez P et al (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 141(9):921–932CrossRef Ayerbe J, Lobato R, de la Cruz J, Alday R, Rivas J, Gómez P et al (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 141(9):921–932CrossRef
18.
go back to reference Flickinger J, Kondziolka D, Maitz A, Lunsford L (2003) Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys 56(3):801–806PubMed Flickinger J, Kondziolka D, Maitz A, Lunsford L (2003) Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys 56(3):801–806PubMed
19.
go back to reference Pollock B (2003) Stereotactic radiosurgery for intracranial meningiomas: indications and results. Neurosurg Focus 14(5):E4CrossRefPubMed Pollock B (2003) Stereotactic radiosurgery for intracranial meningiomas: indications and results. Neurosurg Focus 14(5):E4CrossRefPubMed
20.
go back to reference Goodwin J, Crowley J, Eyre H, Stafford B, Jaeckle K, Townsend J (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15(1):75–77CrossRefPubMed Goodwin J, Crowley J, Eyre H, Stafford B, Jaeckle K, Townsend J (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15(1):75–77CrossRefPubMed
21.
go back to reference Grunberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, Russell C, Kabbinavar F, Barger GR, Stelzer KJ, Southwest Oncology Group, Eastern Cooperative Group (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. In: Proceedings of the American Society of Clinical Oncology 20 (abstract 222) Grunberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, Russell C, Kabbinavar F, Barger GR, Stelzer KJ, Southwest Oncology Group, Eastern Cooperative Group (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. In: Proceedings of the American Society of Clinical Oncology 20 (abstract 222)
22.
go back to reference Wen P, Yung W, Lamborn K, Norden A, Cloughesy T, Abrey L et al (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 11(6):853–860CrossRefPubMed Wen P, Yung W, Lamborn K, Norden A, Cloughesy T, Abrey L et al (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 11(6):853–860CrossRefPubMed
23.
go back to reference Norden A, Raizer J, Abrey L, Lamborn K, Lassman A, Chang S et al (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211–217CrossRefPubMed Norden A, Raizer J, Abrey L, Lamborn K, Lassman A, Chang S et al (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211–217CrossRefPubMed
Metadata
Title
Opportunities for clinical research in meningioma
Authors
Michael A. Vogelbaum
C. Leland Rogers
Mark A. Linskey
Minesh P. Mehta
Publication date
01-09-2010
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0375-6

Other articles of this Issue 3/2010

Journal of Neuro-Oncology 3/2010 Go to the issue